Roflumilast does not decrease COPD exacerbations in adequately treated patients, but subgroup analysis allows for shared decision making
Nathanael Sanchez
- 06 Feb 2019
- Vol. 5, Iss: 1, pp 2
TL;DR: A critical appraisal and clinical application of Martinez FJ, Rabe KF, Sethi S, et al.'s trial of Roflumilast and Inhaled Corticosteroid/Long-Acting beta2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND).
read more
Abstract: <p>A critical appraisal and clinical application of Martinez FJ, Rabe KF, Sethi S, et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting beta2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. <em>Am J Respir Crit Care Med</em>. Sep 1 2016;194(5):559-567. doi: <a href="https://doi.org/10.1164/rccm.201607-1349OC">10.1164/rccm.201607-1349OC</a>.</p>
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
References
Strength of Recommendation Taxonomy (SORT): A Patient-Centered Approach to Grading Evidence in the Medical Literature
Mark H. Ebell,Jay Siwek,Jay Siwek,Barry D. Weiss,Steven H. Woolf,Jeffrey Susman,Jeffrey Susman,Bernard Ewigman,Marjorie A. Bowman +8 more
TL;DR: A new grading scale that will be used by several family medicine and primary care journals and allowing readers to learn one taxonomy that will apply to many sources of evidence is developed, called the Strength of Recommendation Taxonomy.
•Journal Article
Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature.
Mark H. Ebell,Jay Siwek,Barry D. Weiss,Steven H. Woolf,Jeffrey Susman,Bernard Ewigman,Marjorie A. Bowman +6 more
TL;DR: The Strength of Recommendation Taxonomy (SOT) as mentioned in this paper is based on the information mastery framework, which emphasizes the use of patient-oriented outcomes that measure changes in morbidity or mortality.
823
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial
Fernando J. Martinez,Fernando J. Martinez,Peter M.A. Calverley,Udo-Michael Goehring,Manja Brose,Leonardo M. Fabbri,Klaus F. Rabe +6 more
TL;DR: It is suggested that roflumilast reduces exacerbations and hospital admissions in patients with severe chronic obstructive pulmonary disease and chronic bronchitis who are at risk of frequent and severe exacerbations despite inhaled corticosteroid and longacting β2 agonist therapy, even in combination with tiotropium.
367
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.
Diana C. Grootendorst,S A Gauw,Renate M. Verhoosel,Peter J. Sterk,Jeannette J Hospers,Dirk Bredenbröker,T.D. Bethke,Pieter S. Hiemstra,Klaus F. Rabe +8 more
TL;DR: Results from in vitro studies with roflumilast indicate that it has anti- inflammatory properties that may be applicable for the treatment of COPD, and this anti-inflammatory effect may in part explain the concomitant improvement in post-bronchodilator FEV1.
293
Roflumilast with long-acting β2 agonists for COPD: influence of exacerbation history
Eric D. Bateman,K. F. Rabe,P. M. Calverley,U. M. Goehring,M. Brose,D. Bredenbröker,Leonardo M. Fabbri +6 more
TL;DR: Roflumilast may be used to reduce exacerbations and improve dyspnoea and lung function, without increasing adverse events in COPD patients receiving concomitant LABAs.
132